Save
Email
Print
ShareFeb. 9, 2010 — Experts from GA2LEN, the Global Allergy and Asthma European Network, and EAACI, the European Academy of Allergy and Clinical Immunology, warn that the older antihistamines in over-the-counter allergy medications -- the most common form of self-medication in allergic rhinitis -- may be hazardous to our health.
A joint report to be published in Allergy reviews new data on the treatment of allergies with older antihistamines compared with newer, second-generation H1-antihistamines. The research was funded by GA2LEN, an EU-funded Network of Excellence.
The findings suggest that first-generation H1-antihistamines not only make patients drowsy, but also reduce rapid eye movement (REM) sleep, impair learning, and reduce efficiency at work the next day. In addition, first-generation H1-antihistamines have been implicated in numerous civil aviation, motor vehicle, and boating accidents, and even deaths as a result of accidental or intentional overdosing in infants and young children. First-generation H1-antihistamines have also been linked to suicide cases in both teenagers and adults.
New generation antihistamines on the contrary have shown an equivalent efficacy to treat symptoms while clinical studies and patients report fewer adverse effects. The review ultimately questions whether, for consumer protection reasons, first generation H1-antihistamines should still be available as over-the-counter self-medication.
Antihistamines are most frequently used drugs for treating seasonal and chronic allergic diseases such as allergic rhinitis, urticaria, atopic dermatitis. More than 30% of the EU and US population are potential users, safety is thus paramount.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by GA2LEN, via AlphaGalileo.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Church MK, Maurer M, Simons FER, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, Holgate ST, Zuberbier T. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy, 2010; DOI: 10.1111/j.1398-9995.2009.02325.x
Note: If no author is given, the source is cited instead.
more 
